

## Changes to Board of Directors

**Sydney, Australia, Monday, 29 March 2021:** Next Science Limited (ASX:NXS) (**Next Science / Company**) advises that the Chair of Next Science, George Savvides AM, has notified the Board that he will not be seeking re-election as a director at the Company's 2021 Annual General Meeting scheduled for 5 May 2021 having served as Chair for nearly three years. Mark Compton AM will assume the role of Chair of Next Science from 5 May 2021.

Attached to this announcement is a letter to shareholders from Mr Savvides, a copy of which will be included in the AGM pack to be posted to shareholders on Thursday, 1 April 2021.

In his advice to shareholders, Mr Savvides said "It has been an honour to preside over the transition of Next Science from its pre commercial research foundations, through to its IPO on the ASX and now moving into an exciting commercial phase of new product launches. I intend to remain an enthusiastic shareholder as the company pursues its future growth strategy. I will look forward to expressing my confidence in the future of the Next Science in person at the AGM on 5 May 2021."

Incoming Chair Mark Compton said "Next Science has been very fortunate to have George as its chairman during its formative stages as a publicly listed company and beyond IPO. George has brought a high standard of governance to the company, along with his strong leadership and great integrity and has been laser-focused in pursuing our mission to heal patients and save lives. George will remain a supportive shareholder and an advocate for Next Science in its pursuit to eliminate biofilm-based infection. He leaves our board with the very best wishes and thanks of his colleagues."

Approved and authorised by the Board

Further information:

**Judith Mitchell**

Managing Director, Next Science Limited  
Phone: +61 2 9375 7989  
Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

**Michael Brown**

Pegasus Advisory  
Phone: +61 400 248 080  
Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

## About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: [www.nextscience.com](http://www.nextscience.com).

# NEXT SCIENCE®

29 March 2021

Dear Shareholders,

As we move to finalise the Annual Report to shareholders and prepare for the 2021 Annual General Meeting, I have been considering my three-year board rotation and re-election cycle which is scheduled to go to shareholders at this year's Annual General Meeting on 5 May 2021.

The Board recognises that the Company has been operating in a COVID constrained environment and is preparing for an exciting and significant commercial shift in our US business in the second half of 2021.


In order to best support the Company's plans moving forward, the Board has identified two main areas of focus and attention: firstly, the need for the Chair and CEO to be more easily connected geographically for regular catchups to address the strategic items that arise; and secondly, the Board recognises that once travel restrictions permit, the Managing Director will be investing significant time to build a deeper rapport with the growing US management team and to support our exciting growth plans over the next five plus years. The Chair will need to be available as required to be a local support for investors, local management in Sydney and other stakeholders when the Managing Director is attending to our business offshore.

As I have reflected on my personal situation, including my full board portfolio served from my Melbourne location, and notwithstanding my deep belief and confidence in the future success of Next Science, I have concluded that I would struggle to provide the increased commitment required that we as a Board believe is needed to support the Company in the next few years. With the knowledge that prior to the IPO process we chose to enhance and deepen the capability of the Board by appointing new members, we took some time to consider my possible replacement as Board Chair. As we considered both the annual review conclusions and looked to the succession talent of our Board members, we gained comfort that we have the capability to implement a strong succession plan for replacing myself as Chair through the appointment of fellow board member Mark Compton AM which I, along with all Board members, enthusiastically support.

Mark Compton AM has been gracious to accept the invitation to step up to chair the Board when I hand over the role of chair at the AGM in May. Mark's extensive experience in roles as chairman, including in the ASX listed environment and especially in healthcare, along with his Sydney base and regular international travel program make him perfectly suited to step in and take on the increased governance role we have outlined in our annual review. Further information on Mark's background can be found on page 25 of Next Science's 2020 Annual Report.

It has been an honour to preside over the transition of Next Science from its pre-commercial research foundations, through to its IPO on the ASX and now moving into an exciting commercial phase of new product launches. I intend to remain an enthusiastic shareholder as the Company pursues its future growth strategy. I will look forward to expressing my confidence in the future of Next Science in person at the AGM on 5 May 2021.

Yours sincerely,



**George Savvides AM**  
Chair, Next Science Limited